(Q53871783)

21 May 2018

title

Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. (English)

1 reference

21 May 2018

author name string

Mayer J

1

1 reference

21 May 2018

Krejcí M

2

1 reference

21 May 2018

Doubek M

3

1 reference

21 May 2018

Pospísil Z

4

1 reference

21 May 2018

Brychtová Y

5

1 reference

21 May 2018

Tomíska M

6

1 reference

21 May 2018

Rácil Z

7

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 April 2005

1 reference

21 May 2018

Bone Marrow Transplantation

published in

1 reference

21 May 2018

volume

35

1 reference

21 May 2018

issue

7

1 reference

21 May 2018

page(s)

699-705

1 reference

21 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704829

exact match

0 references

cites work

Nonmalignant late effects after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Diagnosis and clinical management of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Intra-arterial catheter directed therapy for severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

inferred from DOI database lookup

7 January 2021

based on heuristic

High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

inferred from DOI database lookup

7 January 2021

based on heuristic

Intra-mesenteric artery steroid administration relieved severe refractory gastro-intestinal graft-vs.-host disease in an allogeneic bone marrow transplantation patient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704829

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1704829

1 reference

21 May 2018

1 reference

21 May 2018